Update on malignant pleural mesothelioma

Seminars in Respiratory and Critical Care Medicine

Volumn 32, Issue 1, 2011, Pages 102-110

  Campbell, Nicholas Paul ^a   Kindler, Hedy Lee ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

asbestos; biomarkers; Mesothelioma; multimodality; pemetrexed

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CBP 501; CEDIRANIB; CISPLATIN; CIXUTUMUMAB; ERLOTINIB; EVEROLIMUS; FRESOLIMUMAB; GEFITINIB; GEMCITABINE; IMATINIB; MESOTHELIN; MITOMYCIN; MORAB 009; NAVELBINE; OSTEOPONTIN; PEMETREXED; PLACEBO; RALTITREXED; SORAFENIB; SS 1P; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; VATALANIB; VINBLASTINE; VORINOSTAT;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; DISEASE SEVERITY; ENVIRONMENTAL EXPOSURE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG RESECTION; MALIGNANT PLEURAL MESOTHELIOMA; PLEURA MESOTHELIOMA; PLEURECTOMY; PLEURODESIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; THORACOCENTESIS; THORACOSCOPY; THORAX RADIOGRAPHY; VIDEO ASSISTED THORACOSCOPIC SURGERY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASBESTOS; GPI-LINKED PROTEINS; HUMANS; MASS SCREENING; MESOTHELIOMA; OSTEOPONTIN; PLEURAL NEOPLASMS; PROGNOSIS; QUALITY OF LIFE; TUMOR MARKERS, BIOLOGICAL;

EID: 79954595092     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0031-1272874     Document Type: Article

References (79)

1. Teta M J., Mink P J., Lau E, Sceurman B K., Foster E D. US mesothelioma patterns 1973-2002: indicators of change and insights into background rates. Eur J Cancer Prev 2008 17 6 525-534
2. Wagner J C., Sleggs C A., Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960 17 260-271
3. Flores R M., Riedel E, Donington J S. et al. Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population. J Thorac Oncol 2010 5 10 1649-1654
4. Hodgson D C., Gilbert E S., Dores G M. et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 2007 25 12 1489-1497 (Pubitemid 46759253)
5. Roushdy-Hammady I, Siegel J, Emri S, Testa J R., Carbone M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 2001 357 9254 444-445 (Pubitemid 32156148)
6. Gee G V., Stanifer M L., Christensen B C. et al. SV40 associated miRNAs are not detectable in mesotheliomas. Br J Cancer 2010 103 6 885-888
7. Donaldson K, Murphy F A., Duffin R, Poland C A. Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma. Part Fibre Toxicol 2010 7 5
8. Price B, Ware A. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol 2004 159 2 107-112 (Pubitemid 38082517)
9. Hodgson J T., McElvenny D M., Darnton A J., Price M J., Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005 92 3 587-593 (Pubitemid 40395543)
10. LaDou J, Castleman B, Frank A et al. The case for a global ban on asbestos. Environ Health Perspect 2010 118 7 897-901
11. Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients, I: Diagnosis. Cancer 1993 72 2 389-393 (Pubitemid 23193443)
12. Husain A N., Colby T V., Ordóñez N G. et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009 133 8 1317-1331
13. Rusch V, Giroux D, Edwards J et al. Initial analyses of the IASLC International Database for Malignant Pleural Mesothelioma (MPM). [abstract B1.7] Proc IASLC 2009 4 9
14. Herndon J E., Green M R., Chahinian A P., Corson J M., Suzuki Y, Vogelzang N J. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998 113 3 723-731 (Pubitemid 28130949)
15. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus P E., Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998 16 1 145-152 (Pubitemid 28041592)
16. Francart J, Vaes E, Henrard S et al. A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials. Eur J Cancer 2009 45 13 2304-2311
17. Fennell D A., Parmar A, Shamash J et al. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 2005 23 1 184-189 (Pubitemid 41702637)
18. Gordon G J., Dong L, Yeap B Y. et al. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. J Natl Cancer Inst 2009 101 9 678-686
19. Butchart E G., Ashcroft T, Barnsley W C., Holden M P. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: experience with 29 patients. Thorax 1976 31 1 15-24
20. Sugarbaker D J., Strauss G M., Lynch T J. et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 1993 11 6 1172-1178 (Pubitemid 23163360)
21. Rusch V W., From the International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995 108 4 1122-1128
22. Ray M, Kindler H L. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest 2009 136 3 888-896
23. Robinson B W., Creaney J, Lake R et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003 362 9396 1612-1616 (Pubitemid 37443528)
24. Creaney J, Olsen N J., Brims F et al. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomarkers Prev 2010 19 9 2238-2246
25. Creaney J, Yeoman D, Naumoff L K. et al. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007 62 7 569-576 (Pubitemid 47056881)
26. Wheatley-Price P, Yang B, Patsios D et al. Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 2010 28 20 3316-3322
27. Pass H I., Lott D, Lonardo F et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005 353 15 1564-1573 (Pubitemid 41434635)
28. Park E K., Sandrini A, Yates D H. et al. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am J Respir Crit Care Med 2008 178 8 832-837
29. Creaney J, Yeoman D, Demelker Y et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 2008 3 8 851-857
30. Flores R M., Pass H I., Seshan V E. et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008 135 3 620-626, 626, e1-e3
31. Scherpereel A, Astoul P, Baas P et al, European Respiratory Society/European Society of Thoracic Surgeons Task Force. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010 35 3 479-495
32. Treasure T, Waller D, Tan C et al. The mesothelioma and radical surgery randomized controlled trial: the Mars feasibility study. J Thorac Oncol 2009 4 10 1254-1258
33. Boutin C, Rey F, Viallat J R. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma: a randomized trial of local radiotherapy. Chest 1995 108 3 754-758
34. O'Rourke N, Garcia J C., Paul J, Lawless C, McMenemin R, Hill J. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol 2007 84 1 18-22 (Pubitemid 47030694)
35. Tsao A S., Wistuba I, Roth J A., Kindler H L. Malignant pleural mesothelioma. J Clin Oncol 2009 27 12 2081-2090
36. Gupta V, Mychalczak B, Krug L et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2005 63 4 1045-1052 (Pubitemid 41505282)
37. Gupta V, Krug L M., Laser B et al. Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy. J Thorac Oncol 2009 4 6 746-750
38. Allen A M., Czerminska M, Jänne P A. et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 2006 65 3 640-645 (Pubitemid 43795851)
39. Weder W, Kestenholz P, Taverna C et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004 22 17 3451-3457 (Pubitemid 41103650)
40. Flores R M., Krug L M., Rosenzweig K E. et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol 2006 1 4 289-295 (Pubitemid 47163979)
41. Weder W, Stahel R A., Bernhard J et al, Swiss Group for Clinical Cancer Research. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007 18 7 1196-1202 (Pubitemid 47244366)
42. Rea F, Marulli G, Bortolotti L et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results. Lung Cancer 2007 57 1 89-95 (Pubitemid 46843340)
43. Krug L M., Pass H I., Rusch V W. et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009 27 18 3007-3013
44. Van Schil P E., Baas P, Gaafar R et al, European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J 2010 36 6 1362-1369
45. Vogelzang N J., Rusthoven J J., Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003 21 14 2636-2644 (Pubitemid 46606305)
46. van Meerbeeck J P., Gaafar R, Manegold C et al, European Organisation for Research and Treatment of Cancer Lung Cancer Group National Cancer Institute of Canada. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005 23 28 6881-6889
47. Santoro A, O'Brien M E., Stahel R A. et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008 3 7 756-763
48. Muers M F., Stephens R J., Fisher P et al, MS01 Trial Management Group. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008 371 9625 1685-1694 (Pubitemid 351671885)
49. Jassem J, Ramlau R, Santoro A et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008 26 10 1698-1704
50. Zalcman G, Margery J, Scherpereel A et al. IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma. [abstract 7020] J Clin Oncol 2010 28 15 Suppl
51. Study of CBP501 + pemetrexed + cisplatin in patients with solid tumors (phase I) and patients with malignant pleural mesothelioma (phase II). Available at: http://www.clinicaltrials.gov/ct2/results?term=cbp + 501 + mesothelioma Accessed October 10, 2010
52. Garland L, Chansky K, Wozniak A et al. SWOG S0509: A phase II study of novel oral antiangiogenic agent AZD2171 (NSC-732208) in malignant pleural mesothelioma. [abstract 7511] J Clin Oncol 2009 27 15 Suppl
53. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008 44 1 46-53 (Pubitemid 350262830)
54. Kindler H L. Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol 2008 9 2-3 171-179
55. Anti-TGF monoclonal antibody (GC1008) in relapsed malignant pleural mesothelioma. Available at: http://www.clinicaltrials.gov/ct2/results?term= gc1008 + mesothelioma Accessed October 10, 2010
56. Anti-TGF monoclonal antibody (GC1008) in relapsed malignant pleural mesothelioma. Available at: http://www.clinicaltrials.gov/ct2/results?term=imc + a12 + mesothelioma Accessed October 10, 2010
57. Gregorc V, Zucali P A., Santoro A et al. Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol 2010 28 15 2604-2611
58. Everolimus in treating patients with pleural malignant mesothelioma that cannot be removed by surgery. Available at: http://www.clinicaltrials.gov/ct2/ results?term=rad + 001 + mesothelioma Accessed October 10, 2010
59. Krug L M., Curley T, Schwartz L et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 2006 7 4 257-261 (Pubitemid 43280028)
60. Scagliotti G V., Shin D M., Kindler H L. et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003 21 8 1556-1561 (Pubitemid 46594110)
61. Baas P, Ardizzoni A, Grossi F et al, EORTC Lung Cancer Group. The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). Eur J Cancer 2003 39 3 353-357 (Pubitemid 36140053)
62. Wang Y, Zhao R, Chattopadhyay S, Goldman I D. A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate, pemetrexed. Cancer Res 2002 62 22 6434-6437 (Pubitemid 35364101)
63. van den Bogaert D P., Pouw E M., van Wijhe G et al. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J Thorac Oncol 2006 1 1 25-30 (Pubitemid 47164017)
64. Ceresoli G L., Zucali P A., Gianoncelli L, Lorenzi E, Santoro A. Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 2010 36 1 24-32
65. Bang K, Mazurek J M., Storey E et al, Centers for Disease Control and Prevention (CDC). Malignant mesothelioma mortalityUnited States, 1999-2005. MMWR Morb Mortal Wkly Rep 2009 58 15 393-396
66. Castagneto B, Botta M, Aitini E et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008 19 2 370-373 (Pubitemid 351201722)
67. Ceresoli G L., Zucali P A., Favaretto A G. et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006 24 9 1443-1448 (Pubitemid 46622011)
68. Ceresoli G L., Castagneto B, Zucali P A. et al. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Br J Cancer 2008 99 1 51-56 (Pubitemid 351920240)
69. Lee C W., Murray N, Anderson H, Rao S C., Bishop W. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer 2009 64 3 308-313
70. Righi L, Papotti M G., Ceppi P et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 2010 28 9 1534-1539
71. Steele J P., Shamash J, Evans M T., Gower N H., Tischkowitz M D., Rudd R M. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000 18 23 3912-3917
72. La Verde N, Bramati A, Cinquini M et al. A retrospective analysis of second-line chemotherapy for malignant pleural mesothelioma (MPM). [abstract 7040] J Clin Oncol 2010 28 15 Suppl
73. Reck M, Krzakowski M, Jassem J et al. Randomized, multicenter phase III study of ranpirnase plus doxorubicin (DOX) versus DOX in patients with unresectable malignant mesothelioma (MM). [abstract 7507] J Clin Oncol 2009 27 15 Suppl
74. Stebbing J, Powles T, McPherson K et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2009 63 1 94-97
75. Zucali P A., Ceresoli G L., Garassino I et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 2008 112 7 1555-1561 (Pubitemid 351441168)
76. Dubey S, Jänne P A., Krug L et al. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol 2010 5 10 1655-1661
77. Nowak A, Millward M, Francis R J. et al. Final results of a phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). [abstract 7036] J Clin Oncol 2010 28 15 Suppl
78. Karrison T, Kindler H L., Gandara D R. et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. [abstract] J Clin Oncol 2007 25 18 Suppl 391s
79. Krug L M., Dao T, Brown A B. et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother 2010 59 10 1467-1479